Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 28, 2016. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMR) and Persons Closely Associated (PCA) with them.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific share transactions.
Material Changes and Transactions
The filing details four specific transactions involving Ms. E. Walmsley (CEO Designate) and Mr. D. Owen (PCA of Ms. Walmsley) on October 28, 2016:
- Transfer to Spouse: Ms. Walmsley transferred 60,000 Ordinary Shares to her spouse (Mr. Owen) for nil consideration (£0.00).
- Receipt from Spouse: Mr. Owen received the aforementioned 60,000 Ordinary Shares from Ms. Walmsley for nil consideration.
- Sale by CEO Designate: Ms. Walmsley sold 40,000 Ordinary Shares on the London Stock Exchange at a price of £16.4503 per share.
- Sale by PCA: Mr. Owen sold 60,000 Ordinary Shares on the London Stock Exchange at a price of £16.4503 per share.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Ms. E. Walmsley, identified as CEO Designate, executed a sale of 40,000 shares and a transfer of 60,000 shares on the same day.
- Mr. D. Owen, a person closely associated with the CEO Designate, received 60,000 shares via transfer and subsequently sold 60,000 shares.
- All sales were executed on the London Stock Exchange at a uniform price of £16.4503.
- The transfer between the CEO Designate and her spouse was conducted for nil consideration.